LSN is in a pivotal position in the early-stage life science arena because we have four distinct global data sources to search and find targets across the silos of drugs, devices, diagnostics, and digital health. LSN sells the Business Development Database, that has 64k companies, to BIG Pharma and service providers who seek early-stage assets for pipeline development or to sell services to. LSN also has a private SalesForce.com database that consists of all the early stage RESI attendees over a 10-year period which nets out to about 8,000 startups, plus all the accounts that LSNs business development staff manage in the five geographical turf the reps manage. Each rep manages around 2,500 early-stage companies per turf and LSN has ongoing profiles on 12,500 of these startups. The LSN newsletter has a readership of 50,000 and we can use this audience to do target mailings.